UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (~~date~~Date of earliest event reported): July ~~June 27~~26, 2011

JIANGBO PHARMACEUTICALS, INC.

(Exact name of ~~registrant~~Registrant as ~~specified~~Specified in ~~charter~~its Charter)

~~Florida~~FLORIDA (State or Other Jurisdiction of Incorporation) 001-34763 (Commission File Number) 65-1130026 (IRS Employer Identification No.)

~~(State~~25 orHaihe ~~other~~Road, ~~jurisdiction~~Laiyang Economic Development Laiyang City, Yantai, Shandong Province, People’s Republic of ~~incorporation~~China 265200 (Address of Principal Executive Offices) N/A (Zip Code)

001-34763	65-1130026
(Commission File Number)	(IRS Employer Identification No.)

(86)535-7282997

25(Registrant's ~~Haihe~~telephone ~~Road~~number, ~~Laiyang~~including ~~Economic~~area ~~Development Laiyang City, Yantai, Shandong Province, People’s Republic of China 265200~~code)

~~(Address~~Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of ~~principal~~the ~~executive~~registrant ~~offices~~under ~~and~~any ~~zip~~of ~~code~~the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (~~0086)~~17 ~~535-7282997~~CFR 230.425)

~~(Registrant's~~¨ ~~telephone~~Soliciting ~~number~~material ~~including~~pursuant ~~area~~to ~~code~~Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

~~(Registrant's~~¨ ~~former~~Pre-commencement ~~name~~communications orpursuant ~~former~~to ~~address,~~Rule if14d-2(b) ~~changed~~under ~~since~~the ~~last~~Exchange ~~report~~Act (17 CFR 240.14d-2(b))

~~Check~~¨ ~~the appropriate box below if the Form 8~~Pre-Kcommencement ~~filing~~communications ispursuant ~~intended~~ to ~~simultaneously~~Rule ~~satisfy~~13e-4(c) ~~the filing obligation of registrant~~ under ~~any~~the ofExchange ~~the~~Act ~~following~~(17 ~~provisions:~~CFR 240.13e-4(c))

~~o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)~~1

~~o Soliciting~~Section ~~material~~3 ~~pursuant~~– toSecurities ~~Rule~~and ~~14a-12(b)~~Trading ~~under the Exchange Act (17 CFR 240.14a-12(b))~~Market

~~o Pre-commencement~~Item ~~communications~~3.01 ~~pursuant~~Notice of Delisting or Failure to ~~Rule~~Satisfy ~~14d-2(b)~~a ~~under~~Continued ~~the~~Listing ~~Exchange~~Rule ~~Act~~or ~~(17~~Standard; ~~CFR~~Transfer ~~240~~of Listing.~~14d-2(b))~~

~~o Pre-commencement~~On ~~communications~~July ~~pursuant~~26, to2011, ~~Rule~~Jiangbo ~~13e-4~~Pharmaceuticals, Inc. (cthe "Company") ~~under~~received a letter (the ~~Exchange~~"Letter") ~~Act~~from ~~(17~~the ~~CFR~~Listing ~~240.13e-4~~Qualifications Staff of the NASDAQ Stock Market LLC (c"Nasdaq")). The Letter indicates that Staff believes that the continued listing of the Company’s securities on Nasdaq is no longer warranted and has determined to delist the Company for the following reasons:

~~Item~~(1) Public ~~5.07~~interest ~~Submission~~concerns under Nasdaq Listing Rule 5101 raised by the efforts of ~~Matters~~the Company and its Chairman to aobstruct ~~Vote~~the ofindependent ~~Security~~internal ~~Holders.~~investigation authorized by its Audit Committee, and the failure to allow the Audit Committee to fulfill its responsibilities and duties;

~~Jiangbo Pharmaceuticals, Inc.~~ (~~the~~2) The “Company~~”),~~’s ~~held~~failures ~~its~~to ~~annual~~comply ~~meeting~~with ofListing ~~stockholders on June 28, 2011, at 9:00 a.m. Beijing~~ Standard ~~Time~~Rule 5605(~~local time~~c)~~, which is equivalent to June 27, 2011 at 9:00 p.m. U.S. Eastern Standard Time~~ (~~the “Annual Meeting”~~3). Atand ~~the Annual Meeting~~IM-5605-5, ~~the~~which ~~stockholders~~sets ~~elected~~forth ~~each of~~ the ~~following~~responsibilities ~~nominees~~and toauthority ~~the board~~ of ~~directors of~~ the ~~Company~~Audit ~~for a one-year term: Mr. Cao Wubo~~Committee, ~~Mr.~~as ~~Feng~~well ~~Xiaowei, Ms. Huang Lei, Mr. Ge Jian and Mr. George Zhou. Additionally, the stockholders ratified the appointment of Marcum Bernstein & Pinchuk LLP~~ as the ~~Company’s~~statutory ~~independent~~responsibilities ~~auditors for the fiscal year ending June 30, 2011~~ and ~~approved~~authority ~~the Jiangbo Pharmaceuticals, Inc. 2011 Omnibus Securities and Incentive Plan (the “Plan”). The Company’s board~~ of ~~directors had previously adopted~~ the ~~Plan,~~Audit ~~subject~~Committee ~~to stockholder approval. The description of the Plan~~ set forth in ~~the~~Section ~~Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on May 31, 2011~~ 10A(~~the "Definitive Proxy Statement"~~m)(2) ~~is incorporated herein by reference in response to this Item. The description~~ of the ~~Plan~~Securities isExchange ~~qualified~~Act ~~in its entirety by reference to the full text~~ of ~~the~~1934; ~~Plan which was attached to the Definitive Proxy Statement as Appendix D~~ and ~~is incorporated herein by reference.~~

~~The~~(3) the ~~voting~~failure atby the ~~Annual~~Company ~~Meeting~~to ~~was~~comply aswith ~~follows:~~the Audit Committee composition requirements of Listing Rule 5605(c)(2)(A) .

~~1. Election~~Unless the Company requests an appeal of ~~Directors~~Nasdaq's determination to delist by August 2, 2011, trading of the Company's shares of common stock will be suspended at the opening of business on August 4, 2011, and a Form 25- NSE will be filed with the Securities and Exchange Commission, which will result in the Company's securities being removed from listing and registration on Nasdaq.

Nominee	For	Against	Withheld	Broker Non-Votes
Cao Wubo	7,873,331	-	940,788	-
Feng Xiaowei	7,962,829	-	851,290	-
Huang Lei	7,977,602	-	836,517	-
Ge Jian	7,977,829	-	836,290	-
George Zhou	7,963,118	-	851,001	-

The Company has decided to focus on addressing current issues facing the Company and its business and will not appeal Nasdaq's determination.

~~2. Ratification~~Section of9 ~~Marcum~~– ~~Bernstein~~Financial &Statements ~~Pinchuk~~and ~~LLP as the Company’s Independent Auditors~~Exhibits

For		Against		Abstain		Broker Non-Votes
11,146,831		125,045		472		-

Item 9.01 Financial Statements and Exhibits

~~3. Adoption~~(d) ~~of the Plan~~Exhibits

For		Against		Abstain		Broker Non-Votes
7,918,256		893,756		2,114		-

99.1 Press release announcing Receipt of Nasdaq Delisting Notice.

~~SIGNATURES~~2

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~SIGNATURE

~~JIANGBO~~Pursuant ~~PHARMACEUTICALS~~to the requirements of the Securities Exchange Act of 1934, ~~INC.~~the ~~By:~~registrant ~~/s/~~has ~~Jin~~duly ~~Linxian~~caused ~~Name:~~this ~~Jin~~report ~~Linxian~~to ~~Title:~~be ~~Chief~~signed ~~Executive~~on ~~Officer~~its behalf by the undersigned hereunto duly authorized.

Dated: June 30, 2011

	JIANGBO PHARMACEUTICALS, INC.,
	a Florida corporation

Dated: July 31, 2011	By:	/s/ Jin Linxian
		Jin Linxian Chief Executive Officer

Filing Compare · Jiangbo Pharmaceuticals, Inc.